Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ACTM-838 |
| Synonyms | |
| Therapy Description |
ACTM-838 is an attenuated bacterial strain carrying engineered IL-15 and constitutively active STING payloads, which may enhance antitumor immune response and reduce tumor growth (Journal for ImmunoTherapy of Cancer 2023;11:408). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ACTM-838 | ACTM838|ACTM 838 | ACTM-838 is an attenuated bacterial strain carrying engineered IL-15 and constitutively active STING payloads, which may enhance antitumor immune response and reduce tumor growth (Journal for ImmunoTherapy of Cancer 2023;11:408). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06336148 | Phase I | ACTM-838 | A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors | Terminated | USA | AUS | 0 |